Although each type of Vβ- or Vα-specific CAR-T cell can only treat a fraction of T cell leukemia or lymphoma cells, they can target all TCRαβ+ tumor cells after TCR Vα or Vβ CAR-T cells have been developed for all subtypes. This evidence concerns the gene COX5A and neoplasm.